GLP-1 analog diabetes treatment Trulicity is on the rise. In the third quarter of last year, sales increased by 22% compared to the same period last year, continuing to grow. Attention is drawn to the competitive drug Ozempic. The pharmaceutical industry predicts that Ozempic will be a strong opponent of Trulicity. In the global market, Ozempic has already surpassed Trulicity sales. According to IQVIA, a pharmaceutical market research firm, Trulicity's sales in the third quarter were 15.8 billion won. It increased by 22.3% compared to 12.9 billion won in the third quarter of last year. Trulicity is a GLP-1 analog diabetes treatment. GLP-1 analogs are drugs developed using GLP-1 (Glucagon-Like Peptide-1) hormones that